Cargando…

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

The treatment of chronic myeloid leukemia (CML) has been advanced by the development of small-molecule tyrosine kinase inhibitors (TKIs), which target the fusion protein BCR-ABL1 expressed by the Philadelphia chromosome. Ponatinib is a 3rd generation TKI that binds BCR-ABL1 with high affinity and in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castagnetti, Fausto, Pane, Fabrizio, Rosti, Gianantonio, Saglio, Giuseppe, Breccia, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009177/ https://www.ncbi.nlm.nih.gov/pubmed/33796468 http://dx.doi.org/10.3389/fonc.2021.642005

Ejemplares similares

Treatment Recommendations for Chronic Myeloid Leukemia
por: Baccarani, Michele, et al.
Publicado: (2014)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib
por: Breccia, Massimo, et al.
Publicado: (2016)

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
por: Molica, Matteo, et al.
Publicado: (2019)

Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study
por: Iurlo, Alessandra, et al.
Publicado: (2022)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
por: Annunziata, Mario, et al.
Publicado: (2020)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
por: Gugliotta, Gabriele, et al.
Publicado: (2017)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
por: Specchia, Giorgina, et al.
Publicado: (2021)

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients
por: Ricciardi, Maria Rosaria, et al.
Publicado: (2018)

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia
por: Mancini, Manuela, et al.
Publicado: (2017)

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
por: Soverini, Simona, et al.
Publicado: (2016)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
por: Houshmand, Mohammad, et al.
Publicado: (2022)

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
por: Giles, Francis J., et al.
Publicado: (2017)

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
por: Breccia, Massimo, et al.
Publicado: (2017)

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
por: Price, Kimberly E, et al.
Publicado: (2013)

Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
por: Bocchia, Monica, et al.
Publicado: (2018)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
por: Soverini, Simona, et al.
Publicado: (2019)

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights
por: Iezza, Miriam, et al.
Publicado: (2023)

P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA
por: Müller, Martin C., et al.
Publicado: (2023)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2021)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
por: Jiang, Bo, et al.
Publicado: (2023)

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
por: Hochhaus, Andreas, et al.
Publicado: (2017)

Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
por: Musumeci, Francesca, et al.
Publicado: (2018)

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
por: Dragani, Matteo, et al.
Publicado: (2020)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
por: Luciano, Luigia, et al.
Publicado: (2023)

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
por: García-Gutiérrez, Valentin, et al.
Publicado: (2022)

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
por: Caocci, Giovanni, et al.
Publicado: (2019)

Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Bowel Perforation Secondary to Ponatinib Treatment in a Chronic Myelogenous Leukemia Patient: A Case Report
por: Sallam, Asma, et al.
Publicado: (2021)

Management of Chronic Myeloid Leukemia in Advanced Phase
por: Bonifacio, Massimiliano, et al.
Publicado: (2019)

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia
por: Mancini, Manuela, et al.
Publicado: (2015)

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
por: Fava, Carmen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iua2v359eovmo6ovpko42jmu8c